Main menu


Japanese pharmaceutical company discover coronavirus treatment

 Japanese pharmaceutical company discover coronavirus treatment

Coronavirus overview

Amid outbreaks of respiratory diseases in Wuhan City, Hubei Province, China.

The coronavirus disease (COVID-19) is known as the disease caused by the novel coronavirus, which was first identified

WHO was initially informed on December 31, 2019.

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a global health emergency.

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic.

It is the first such classification since the declaration of the H1N1 influenza epidemic in 2009.

FDA-developed programs have allowed doctors to use all the tools and trials allowed during the pandemic to come up with a cure or any thread that leads us to treat this new virus.

New Japanese discovery could cure coronavirus

The Japanese company Shionogi has announced that it is about to detect new drug tablets that are working to treat COVID-19, an antiviral.

The Japanese company is working hard to provide this treatment in the Japanese market.

The World Health Organization (WHO) said on the end of coronavirus 2022

The "acute phase" of the epidemic could be over by the middle of this year if about 70 per cent of the world is vaccinated.

Clinical Trials Phase

After the treatment passed the initial clinical experimental phase in the second phase of development, Shionogi applied for approval of the strength of evidence that the antiviral reduces the viral effect and some symptoms.

The second phase of the trial brought together 428 COVID-19 patients with mild to moderate severity and administered the new medication once a day for five days.

At the end of the treatment period, five days later, Chiunogi saw little difference in the average time-weighted change in the total of 12 symptoms of COVID-19.

This caused the study to not be able to reach the basic clinical endpoint. Chiunogi did not find a significant improvement in the respiratory symptoms of patients who received experimental drug doses.

Pfizer's oral drug Paxlovid for coronavirus has failed to reach its primary clinical endpoint.

It also failed to alleviate all symptoms over four consecutive days in a study of unvaccinated patients (unvaccinated against the virus), low-risk, and higher-risk patients, but was shown to reduce hospitalization and death in that trial and in another study.

Chiunugi has yet to publish details and data on the impact of new HIV treatment on hospitalization and death.

This makes the destruction and killing of the virus the strongest evidence that the drug works.

By day four, Chiunogi had witnessed significant reductions in the strength of the virus, one of the primary endpoints.

"The proportion of people infected with a positive virus, which was less than 10% in people who took the new treatment doses."

Chiunogi is collecting further evidence of the effectiveness of new drug tablets in ongoing studies.

In the late stages, more than 1,000 patients with mild to moderate symptoms have COVID-19 and 300 to 600 people have either asymptomatic or only mild symptoms.

Approve the marketing of treatment

With Omicron's recent pressure on the supply of existing treatment and specifically on Chiunogi partners

Chiunogi does not wait for data to submit a request for approval.

Japan-based pharmaceutical manufacturer Osaka requested conditional approval in Japan.

If approved, Chiunogi's new pharmaceutical tablets will join Merck's Lagevrio and Pfizer Paxlovid In the list of oral anti-coronavirus available in Japan